BIOMAT Database Logo BIOMAT Database Logo

Effects of a cysteinyl leukotriene antagonist, ONO-1078 (pranlukast), on total airway resistance after antigen challenge in sensitized guinea pigs. 1997

S Narita, and K Asakura, and H Shirasaki, and A Kataura
Department of Otolaryngology, Sapporo Medical University, School of Medicine, Japan.

OBJECTIVE To define the role of leukotriene (LT) in allergic rhinitis, we examined the effects of a cysteinyl (Cys) LT antagonist (ONO-1078, pranlukast). METHODS Actively sensitized Dunkin-Hartley guinea pigs. METHODS ONO-1078 (pranlukast), 3-100 mg/kg p.o. 1 h before antigen challenge. METHODS Nasal symptoms (sneezing, nasal scratches), changes of total airway resistance (TAR by plethysmography) and eosinophil infiltration into the nasal mucosa were determined following topical antigen (OA) challenge. Dunnet's test (TAR and symptoms) and the Mann-Whitney U-test (eosinophils) were applied. RESULTS Control animals showed bi-phasic nasal responses, peaking 10 min and 240 min after the topical antigen challenge, respectively. While the early-phase response was characterized by nasal symptoms of sneezing and scratching accompanied by the increase in TAR, the late-phase was characterized by an increase in TAR accompanied by eosinophil infiltration into nasal mucosa. The nasal symptoms (sneezing and scratching) were not inhibited by pretreatment with ONO-1078 at doses up to 100 mg/kg (p.o., n = 15). Although early peak responses of TAR were not affected with even the highest dose (30 mg/kg, p.o., n = 6), late-phase TAR peak response (control: 174.8 +/- 8.2%, n = 6) were significantly inhibited by 10 mg/ kg (142.7 +/- 15.8%; p < 0.05, n = 6) and 30 mg/kg (118.0 +/- 6.6%; p < 0.01, n = 6) of ONO-1078 (p.o.). In addition, the eosinophil infiltration induced by the antigen was not inhibited by ONO-1078 (30 and 100 mg/kg, p.o., n = 6). CONCLUSIONS Our results suggest that Cys LT may play an important role in the late-phase increase in TAR in the guinea pig model of allergic rhinitis.

UI MeSH Term Description Entries
D009297 Nasal Mucosa The mucous lining of the NASAL CAVITY, including lining of the nostril (vestibule) and the OLFACTORY MUCOSA. Nasal mucosa consists of ciliated cells, GOBLET CELLS, brush cells, small granule cells, basal cells (STEM CELLS) and glands containing both mucous and serous cells. Nasal Epithelium,Schneiderian Membrane,Epithelium, Nasal,Membrane, Schneiderian,Mucosa, Nasal
D010047 Ovalbumin An albumin obtained from the white of eggs. It is a member of the serpin superfamily. Serpin B14
D010991 Plethysmography Recording of change in the size of a part as modified by the circulation in it. Plethysmographies
D002867 Chromones 1,4-Benzopyrones,Chromone,1,4 Benzopyrones
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004804 Eosinophils Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin. Eosinophil
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000403 Airway Resistance Physiologically, the opposition to flow of air caused by the forces of friction. As a part of pulmonary function testing, it is the ratio of driving pressure to the rate of air flow. Airway Resistances,Resistance, Airway,Resistances, Airway

Related Publications

S Narita, and K Asakura, and H Shirasaki, and A Kataura
Effect of a peptide leukotriene antagonist, ONO-1078 on antigen-induced airway microvascular leakage in actively sensitized guinea pigs.
January 1992, Life sciences,
S Narita, and K Asakura, and H Shirasaki, and A Kataura
Effects of a specific cysteinyl leukotriene antagonist, pranlukast, on antigen-induced cysteinyl leukotriene-mediated rhinitis in guinea pigs.
December 1997, Japanese journal of pharmacology,
S Narita, and K Asakura, and H Shirasaki, and A Kataura
Inhibition of human eosinophil activation by a cysteinyl leukotriene receptor antagonist (pranlukast; ONO-1078).
June 2003, The Journal of asthma : official journal of the Association for the Care of Asthma,
S Narita, and K Asakura, and H Shirasaki, and A Kataura
The effects of a cysteinyl leukotriene antagonist (ONO-1078) on antigen-induced responses in allergic sheep.
March 1993, Prostaglandins, leukotrienes, and essential fatty acids,
S Narita, and K Asakura, and H Shirasaki, and A Kataura
Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.
August 2001, Internal medicine (Tokyo, Japan),
S Narita, and K Asakura, and H Shirasaki, and A Kataura
Effect of ONO-1078, a leukotriene antagonist, on capsaicin- and substance P-induced bronchoconstriction and airway microvascular leakage in guinea pigs.
May 1996, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
S Narita, and K Asakura, and H Shirasaki, and A Kataura
Inhibition of Allergic Bronchoconstriction in Guinea Pigs and in Asthmatics by the Leukotriene Antagonist ONO-1078.
January 1992, International archives of allergy and immunology,
S Narita, and K Asakura, and H Shirasaki, and A Kataura
Inhibition of endogenous leukotriene-mediated lung anaphylaxis in guinea pigs by a novel receptor antagonist ONO-1078.
January 1990, International archives of allergy and applied immunology,
S Narita, and K Asakura, and H Shirasaki, and A Kataura
Effects of ONO-1078, a leukotriene antagonist, on cardiovascular responses induced by vagal stimulation, capsaicin, and substance P in guinea pigs.
November 1995, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
S Narita, and K Asakura, and H Shirasaki, and A Kataura
Inhibition by a novel peptide leukotriene receptor antagonist ONO-1078 of airway wall thickening and airway hyperresponsiveness to histamine induced by leukotriene C4 or leukotriene D4 in guinea-pigs.
October 1994, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
Copied contents to your clipboard!